My name is Inês Ramos and I work as a data analyst at the Portuguese Medicines and Health Products Authority (aka Infarmed), where I develop drug utilization studies and policies impact evaluations using primarily drug reimbursement claims .
One of my main projects at work is a study of the treatment pathways in diabetes using reimbursement claims. We hope to publish the first paper arising from this project soon.
While I was doing the bibliographic revision, I stumbled upon the paper 'Characterizing treatment pathways at scale using the OHDSI network' and thought it was an amazing endeavour. So here I am.
I am curious if we could adapt the Portuguese data to the OMOP common data model and, perhaps, participate in a future study. It would be an amazing improvement if we could benchmark the results against results from other countries.
Can you help me satisfy my curiosity?